F. Fakhouri, V. Fremeaux-bacchi, L. H. Noel, H. T. Cook, and M. C. Pickering, C3 glomerulopathy: a new classification, Nat Rev Nephrol, vol.6, issue.8, pp.494-499, 2010.

M. C. Pickering, D. 'agati, V. D. Nester, and C. M. , C3 glomerulopathy: consensus report, Kidney Int, vol.84, issue.6, pp.1079-1089, 2013.

A. Servais, L. H. Noel, and L. T. Roumenina, Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies, Kidney Int, vol.82, issue.4, pp.454-464, 2012.

S. H. Nasr, A. M. Valeri, and G. B. Appel, Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients, Clin J Am Soc Nephrol, vol.4, issue.1, pp.22-32, 2009.

M. C. Pickering, H. T. Cook, and J. Warren, Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H, Nat Genet, vol.31, issue.4, pp.424-428, 2002.

K. Hogasen, J. H. Jansen, T. E. Mollnes, J. Hovdenes, and M. Harboe, Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency, J Clin Invest, vol.95, issue.3, pp.1054-1061, 1995.

C. Nicolas, V. Vuiblet, and V. Baudouin, C3 nephritic factor associated with C3 glomerulopathy in children, Pediatr Nephrol, vol.29, issue.1, pp.85-94, 2014.

S. Sethi, F. C. Fervenza, and Y. Zhang, C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up, Kidney Int, vol.82, issue.4, pp.465-473, 2012.

Q. Chen, D. Muller, and B. Rudolph, Combined C3b and factor B autoantibodies and MPGN type II, N Engl J Med, vol.365, issue.24, pp.2340-2342, 2011.

M. A. Little, P. Dupont, E. Campbell, A. Dorman, and J. J. Walshe, Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk, Kidney Int, vol.69, issue.3, pp.504-511, 2006.

C. M. Legendre, C. Licht, and C. Loirat, Eculizumab in atypical hemolytic-uremic syndrome, N Engl J Med, vol.369, issue.14, pp.1379-1380, 2013.

J. Zuber, F. Fakhouri, L. T. Roumenina, C. Loirat, and V. Fremeauxbacchi, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nat Rev Nephrol, vol.8, issue.11, pp.643-657, 2012.

A. S. Bomback, R. J. Smith, and G. R. Barile, Eculizumab for dense deposit disease and C3 glomerulonephritis, Clin J Am Soc Nephrol, vol.7, issue.5, pp.748-756, 2012.

E. Daina, M. Noris, and G. Remuzzi, Eculizumab in a patient with dense-deposit disease, N Engl J Med, vol.366, issue.12, pp.1161-1163, 2012.

M. Vivarelli, A. Pasini, and F. Emma, Eculizumab for the treatment of dense-deposit disease, N Engl J Med, vol.366, issue.12, pp.1163-1165, 2012.

M. C. Pickering, J. Warren, and K. L. Rose, Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice, Proc Natl Acad Sci, vol.103, issue.25, pp.9649-9654, 2006.

L. C. Herlitz, A. S. Bomback, and G. S. Markowitz, Pathology after eculizumab in dense deposit disease and C3 GN, J Am Soc Nephrol, vol.23, issue.7, pp.1229-1237, 2012.